Drugs / Re-stimulated tumor-infiltrating lymphocytes (TILs)
Re-stimulated tumor-infiltrating lymphocytes (TILs)
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01883297 | Jan 2015 → Jun 2027 expected | fallopian tube carcinoma, ovarian serous adenocarcinoma, primary peritoneal carcinoma | University Health Network, Toronto | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Re-stimulated tumor-infiltrating lymphocytes (TILs) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01883297 ↗ |
| Modality | Cell therapy | “autologous tumor-infiltrating lymphocytes (TILs)” NCT01883297 ↗ |